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Abbreviations: BM, bone marrow; BMMC, bone marrow mononuclear cell; BML, bone marrow lymphocytes; BMT, bone marrow
T lymphocytes; BMTCD25¡, bone marrow T lymphocytes depleted of regulatory T cells; BMSC, bone marrow stromal cells; BrHPP,
bromohydrin-pyrophosphate; CM, central memory; CTRL, control group; DC, dendritic cells; EM, effector memory; IL-2, interleu-
kin 2; IPP, isopentenylpyrophosphate; L-NMMA, NG-methyl-L-arginine acetate salt; MDSC, myeloid-derived suppressor cells; Mev,
mevalonate; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; MM-dia, multiple myeloma
patients at diagnosis; MM-rel, multiple myeloma patients in relapse; MM-rem, multiple myeloma patients in remission; M-MDSC,
monocytic myeloid-derived suppressor cells; pAgs, phosphoantigens; PB, peripheral blood; PBMC, peripheral blood mononuclear
cell; PMN-MDSC, polymorphonuclear myeloid-derived suppressor cells; TCR, T cell receptor; TEMRA, terminally differentiated
effector memory cells; TGF-b, transforming growth factor b; TNF-alfa, tumor necrosis factor alfa; Tregs, regulatory T cells; SEP,
solitary extra-medullary plasmocytoma; ZA, zoledronic acid; 1-MT, 1-methyl tryptophan
Vg9Vd2 T cells have a natural inclination to recognize malignant B cells in vitro via receptors for stress-induced self-
ligands and TCR-dependent recognition of phosphoantigens (pAgs) generated in the mevalonate (Mev) pathway. This
inclination is continuously challenged in vivo by the immune suppression operated by tumor cells. Multiple myeloma
(MM) is a prototypic B-cell malignancy in which myeloma cells subvert the local microenvironment to reshape
antitumor immune responses. In this study, we have investigated the immune competence of bone marrow (BM)
Vg9Vd2 T cells in a large series of MM patients. We have found that the BM microenvironment significantly hampers the
pAg-reactivity of BM Vg9Vd2 T cells, which become largely PD-1C and are surrounded by PD-L1C myeloma cells and
increased numbers of PD-L1Cmyeloid-derived suppressor cells (MDSC). Vg9Vd2 T-cell dysfunction is an early event that
can be already detected in individuals with monoclonal gammopathy of undetermined significance (MGUS) and not
fully reverted even when MM patients achieve clinical remission. Anti-PD-1 treatment increases the cytotoxic potential
of Vg9Vd2 T cells by almost 5-fold after pAg stimulation, and appears to be a promising strategy for effective immune
interventions in MM.
Introduction
Disease progression in MM depends on intrinsic myeloma cell
features but also on the ability of myeloma cells to subvert the
local microenvironment and reshape host immunity to support
their growth, resistance to chemotherapy, and immune escape.1
BM is the privileged site where myeloma cells continuously oper-
ate to escape antitumor immune surveillance. Vg9Vd2 T cells
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are non-conventional T cells halfway between innate and adap-
tive immunity with a natural inclination to react against malig-
nant B cells, including myeloma cells.2 They are equipped with a
peculiar array of receptors for stress-induced self-ligands and a
unique TCR-dependent recognition ability. Normally constitut-
ing only 1–5% of circulating T-cells in healthy adults, Vg9Vd2
T cells increase in microbial infections because they sense infec-
tious agents via the TCR-dependent recognition of pAgs gener-
ated in the Mev and non-Mev pathway of microbial pathogens.
Mammalian cells also generate pAgs, such as isopentenylpyro-
phosphate (IPP), which activate Vg9Vd2 T cells as efficiently as
their natural ligands.3,4 Cell stress and transformation increase
Mev activity and accelerate the formation of intracellular pAgs,
whose accumulation in excess of physiological levels is sensed by
Vg9Vd2 T cells.
IPP levels are increased by zoledronic acid (ZA) that selec-
tively targets farnesyl-pyrophosphate synthase in the Mev path-
way.5 ZA stimulation can be used as a surrogate to interrogate
the immune competence of Vg9Vd2 T cells. Approximately
50% of MM patients are anergic to ZA stimulation at diagnosis
when this assay is performed in peripheral blood (PB) and mono-
cytes are used to generate IPP.6 This anergy is reversible if ZA-
treated dendritic cells (DC), rather than monocytes, are used to
stimulate PB Vg9Vd2 T cells, one possible explanation being
that the former are better IPP producers.7 We have previously
shown in a limited series of patients that BM Vg9Vd2 T cells are
also anergic to pAg stimulation, but the frequency and mecha-
nisms underlying this dysfunction at the tumor site are unknown.
The aim of this study was to interrogate the immune compe-
tence of BM Vg9Vd2 T cells in a large series of MM patients
and provide the groundwork to recover their antitumor effector
functions.
Results
BM Vg9Vd2 T cells are more anergic to pAg stimulation
than PB Vg9Vd2 T cells
In the first series of experiments, ZA-induced Vg9Vd2 T-cell
proliferation was compared in PB and BM samples from MM
patients at diagnosis (MM-dia). Vg9Vd2 T-cell frequencies were
similar in BM and PB (data not shown) but both pooled and
head-to-head data showed that total counts of viable Vg9Vd2 T
cells were significantly higher in PB mononuclear cells (PBMC)
than in BM mononuclear cells (BMMC) (Fig. 1A). Since BM
and PB samples are very different in terms of cell subset composi-
tion (Fig. 1B), BMMC were also stimulated after immunomag-
netic removal of myeloma cells without observing any recovery
of Vg9Vd2 T-cell proliferation (Fig. 1C).
Increased frequencies of BM and PB PMN-MDSC in MM
patients
MDSC are increased in the BM and PB of MM patients, and
suppress the proliferation of conventional T cells.10 MDSC fre-
quency was significantly higher in BM MM than BM control
(CTRL), PB MM, and PB CTRL samples. PB MM also con-
tained significantly higher MDSC percentages than PB CTRL
samples (Fig. 2A). Polymorphonuclear MDSC (PMN-MDSC)
and not monocytic MDSC (M-MDSC) were responsible for the
increased MDSC frequency in MM as previously reported10,11
(see Table S1 for MDSC immunophenotype) (Fig. 2B). Repre-
sentative dot-plots of MDSC frequency in the BM and PB of
MM and CTRL are shown in Fig. 2C.
ZACIL-2 stimulation was also carried out after depletion of
MDSC without observing any recovery of BM Vg9Vd2 T-cell
proliferation (Fig. 2D). Since depletion was suboptimal and
Figure 1. BM Vg9Vd2 T cells are more anergic to pAg stimulation than PB Vg9Vd2 T cells, and not rescued by myeloma cell depletion in MM patients. (A)
Total counts of viable Vg9Vd2 T cells per well after stimulation of MM-dia PBMC and BMMC for 7 d with IL-2 or ZACIL2. Both pooled and head-to-head
data from individual patients are shown. Statistically significant differences are marked with symbols ( P < 0.001; * P D 0.014). (B) Representative SSC vs.
FSC dot plot analyses of freshly isolated BMMC and PBMC samples isolated from MM at diagnosis. (C) Total counts of viable Vg9Vd2 T cells per well after
stimulation of BMMC or CD138-depleted BMMC for 7 d with IL-2 alone or ZACIL2. Myeloma cell removal was not sufficient to reinstate Vg9Vd2 T-cell
proliferation.
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from 6% to 10% of MDSC were left in MM BM samples,
ZACIL-2 stimulation was carried out in the presence of sildena-
fil, 1-methyl tryptophan (1-MT), NG-methyl-L-arginine acetate
salt (L-NMMA), and apocynin (Fig. 2E), but all inhibitors
failed to reinstate ZA-induced Vg9Vd2 BM T-cell proliferation
in MM patients. These inhibitors partially antagonized the
suppressor activity exerted by MM BM MDSC against the
anti-CD3/CD28-induced proliferation of PBT CTRL as previ-
ously reported (Fig. S1).10
ZA-treated DCBM and DCPB effectively induce the
proliferation of autologous PB but not of BM Vg9Vd2 T cells
Next, we investigated whether ZA-treated DC generated from PB
(DCPB) or BM (DCBM) CD14C cells were able to reinstate Vg9Vd2
T-cell proliferation as previously reported in PB.9 As expected, ZA-
treated DCPB significantly reinstated PB Vg9Vd2 T-cell prolifera-
tion, but not that of BMVg9Vd2 T cells (Fig. 3A).
Cross-over experiments were performed in which ZA-treated
DCBM and DCPB were generated from BM and PB CD14C cells
of the same patients and used to stimulate either autologous BM
or PB Vg9Vd2 T cells (Fig. 3B). ZA-treated DCPB and DCBM
effectively induced the proliferation of PB Vg9Vd2 T cells but
both failed to induce that of BM Vg9Vd2 T cells.
Anergy to pAg stimulation is disease-specific and not a
general feature of BM-resident Vg9Vd2 T cells
Next, we investigated whether the anergy of BM MM
Vg9Vd2 T cells was not disease-related but, instead, caused by a
Figure 2. MDSC are increased in PB and BM of MM patients but their removal or inhibition is insufficient to reinstate the pAg reactivity of BM Vg9Vd2 T
cells. (A) MDSC frequencies in the PB and BM of CTRL and MM patients. (B) Frequency of MDSC subsets (PMN-MDSC and M-MDSC) in the PB and BM of
CTRL and MM patients. MDSC and subsets were identified as reported in Table S1. PMN-MDSC were responsible for the increased MDSC frequency in
the PB and BM of MM patients. Statistically significant differences are marked with symbols (always P < 0.001). (C) Representative cytofluorimetric analy-
sis of MDSC in the PB and BM of MM and CTRL. (D) Total counts of viable Vg9Vd2 T cells per well after 7-d stimulation of BMMC or MDSC-depleted
BMMC with IL-2 alone or ZA C IL2. No recovery of BM Vg9Vd2 T-cell proliferation was observed after MDSC removal. (E) Total counts of viable Vg9Vd2 T
cells per well after BMMC stimulation for 7 d with IL-2 or ZA C IL2 in the absence or in the presence of sildenafil (50 mg/mL), 1-MT (1 mM), L-NMMA
(500 mM), and apocynin (100 mM). All treatments failed to reinstate ZA-induced Vg9Vd2 BM T-cell proliferation in MM patients.
www.tandfonline.com e1047580-3OncoImmunology
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distinct activation and/or differentiation state peculiar to the BM
localization. Vg9Vd2 T cells are subcategorized according to
their phenotype, proliferative capacity, migratory propensity,
and effector functions [naive, central memory (CM), effector
memory (EM), and terminally differentiated (TEMRA) subsets],
but the distribution of these subsets was similar in MM and
CTRL BM samples (Fig. S2).
Bromohydrin-pyrophosphate (BrHPP) was also used to chal-
lenge the intrinsic pAg reactivity of MM and CTRL BM
Vg9Vd2 T cells (Fig. 3C). BrHPP is a synthetic IPP analog,
which directly binds TCR and induces Vg9Vd2 T-cell prolifera-
tion in the absence of accessory cells, such as monocytes or
DC.12 The results shown in Fig. 3C clearly indicate that CTRL
BM Vg9Vd2 T cells are fully reactive to ZA- and/or BrHPP-
induced stimulation, whereas both stimulations are ineffective in
MM BMMC.
BM Vg9Vd2 T-cell proliferation is not reinstated by
neutralizing Tregs
We have recently shown that the BM of MM patients is
steadily inhabited by a normal-sized pool of fully functional regu-
latory T cells (Tregs),13 and the latter have been reported to sup-
press PB Vg9Vd2 T-cell proliferation.14 Hence, MM BMMC
were stimulated with ZACIL-2 in the presence of OX-40L or
anti-TGF-b to inhibit the suppressor activity of Tregs,15 but
both treatments were unable to reinstate BM Vg9Vd2 T cell pro-
liferation (Fig. 4A and B).
A final set of experiments was performed in which MM
BMMC, BM lymphocytes (BML), purified BM T (BMT) cells,
and BMT cells depleted of Tregs (BMTCD25¡) were stimulated
with BrHPP and IL-2 but Vg9Vd2 T-cell proliferation was never
recovered even after depletion of Tregs in BMTCD25¡ cultures
(Fig. 4C).
Vg9Vd2 T cells are PD-1C in the BM of MM patients
MM BM Vg9Vd2 T cells showed the highest PD-1 expres-
sion compared with Vg9Vd2 T cells from all other sources
(Fig. 5A). PD-1 expression was significantly higher in CM
Vg9Vd2 T cells, which is the subset with the highest proliferative
capacity (Fig. 5B). MM BM Vg9Vd2 T cells were also the only
cells to significantly upregulate PD-1 expression after ZA stimu-
lation (Fig. 5C).
Increased PD-L1 expression in myeloma cells and MM BM
MDSC
Next, we investigated whether the BM of MM patients was
cohabited by PD-L1C cells that could potentially engage PD-1C
Vg9Vd2 T cells. The majority of myeloma cells (>60%),16 and
a significant proportion of MDSC (>30%) were PD-L1C in
the BM of MM patients (Fig. 5D). MM BM MDSC showed
the highest PD-L1 expression, while MM PB MDSC were
inclined to have higher PD-L1 expression than CTRL PB and
BM MDSC, but the difference was not statistically significant.
Representative dot-plots of PD-L1 expression in myeloma cells
and MDSC from the BM of MM patients are shown in
Fig. 5E.
Figure 3. ZA-treated DCBM and DCPB effectively induce the proliferation
of autologous PB Vg9Vd2 T cells but not that of BM Vg9Vd2 in MM
patients. (A) (left panel): total counts of viable Vg9Vd2 T cells per well
after PBMC stimulation with IL-2, and ZA C IL-2, or after PBL stimulation
with untreated (ZA¡ DC) DCPB and ZA-treated (ZAC DC) DCPB; (right
panel): total counts of viable Vg9Vd2 T cells per well after BMMC stimula-
tion with IL-2 and ZA C IL-2, or after BML stimulation with untreated
(ZA¡ DC) DCBM and ZA-treated (ZAC DC) DCBM. Reactivity to pAg stimula-
tion is reinstated only in PB Vg9Vd2 T cells. Statistically significant differ-
ences are marked with symbols (* P D 0.04). (B) (left panel): total counts
of viable Vg9Vd2 T cells per well after 7-d stimulation of PBT with
untreated (ZA¡ DC) or ZA-treated (ZAC DC) DCPB and DCBM; (right panel)
total counts of viable Vg9Vd2 T cells per well after 7-d stimulation of
BMT with untreated (ZA¡ DC) or ZA-treated (ZAC DC) DCPB and DCBM.
DCPB and DCBM effectively induced the proliferation of PB Vg9Vd2 T cells
but both failed to induce that of BM Vg9Vd2 T cells. (C) Total counts of
viable Vg9Vd2 T cells per well after 7-d stimulation of BMMC from CTRL
and MM patients with IL-2, ZA C IL-2 and BrHPP C IL-2. BM CTRL Vg9Vd2
T cells responded to ZA C IL-2 and BrHPP C IL-2 stimulation, whereas
BM MM Vg9Vd2 T cells failed to respond.
e1047580-4 Volume 4 Issue 11OncoImmunology
D
ow
nl
oa
de
d 
by
 [1
09
.69
.14
4.5
2]
 at
 02
:03
 16
 Se
pte
mb
er 
20
15
 
Anti-PD-1 treatment partly reinstates MM BM Vg9Vd2
T-cell reactivity to pAg stimulation
ZA stimulation was carried out in the presence of increas-
ing anti-PD-1 mAb concentrations and a partial recovery of
BM Vg9Vd2 T-cell proliferation was documented (Fig. 5F
and Fig. S3). To determine whether PD-1 neutralization also
improved the cytotoxic capacity, we evaluated CD107 expres-
sion on Vg9Vd2 T cells after ZA stimulation in the presence
of anti-PD-1 mAb. Data reported in Fig. S4 shows that there
is a direct correlation between ZA-induced Vg9Vd2 T-cell
proliferation and CD107 expression. According to the higher
proliferative response, the frequency of CD107C cells and the
number of CD107 molecules per cell were significantly
higher in CTRL than in MM BM Vg9Vd2 T cells after ZA
stimulation (Fig. 6A), but anti-PD-1 treatment significantly
increased the frequency of CD107C Vg9Vd2 T cells and the
number of CD107 molecules per cell in ZA-stimulated MM
BMMC, whereas isotype control was totally ineffective
(Fig. 6B and Fig. S3).
Defective pAg-reactivity is an early and long-lasting MM
BM Vg9Vd2 T-cell immune dysfunction
ZA stimulation was carried out in BMMC from MGUS, MM
in remission (MM-rem), MM in relapse (MM-rel), and com-
pared with MM-dia values. Data from two patients with solitary
extra-medullary plasmocytoma (SEP) are also shown in Fig. 7A.
Anergy to pAg stimulation was already present in MGUS and
similar to that of MM-dia, MM-rem, and MM-rel, whereas BM
Vg9Vd2 T cells from SEP responded to ZA stimulation
(Fig. 7A).
PD-1 expression in Vg9Vd2 T cells was also similar in
MGUS, MM-dia, and MM-rem, whereas MM-rel showed signif-
icantly higher values than MM-dia (Fig. 7B).
Lastly, the frequency of MDSC and PD-L1 expression in
MDSC were also compared. MM-rem showed a significantly
increased frequency of MDSC, compared with MM-dia and
MM-rel (Fig. 7C), whereas no differences were observed between
MGUS, MM-dia, and MM-rel. Similar proportions of MDSC
were PD-L1C in MM-dia, MM-rem, and MM-rel (Fig. 7D).
Discussion
Our results confirm that the immune contexture in the BM of
MM patients is highly suppressive and that BM Vg9Vd2 T cells
are more dysfunctional than PB Vg9Vd2 T cells when challenged
head-to-head by pAgs in individual patients. Removal of myeloma
cells, MDSC or Tregs, or the functional inhibition of MDSC and
Tregs were insufficient to reinstate MM BM Vg9Vd2 T-cell pAg
reactivity. Gorgun et al.10 have also reported that functional inhi-
bition of BM-derived MDSC is insufficient to recover the reactiv-
ity of autologous T cells to anti-CD3/CD28 stimulation.
The cross-over experiments clearly showed that defective pAg
reactivity is peculiar to MM BM Vg9Vd2 T cells, which do not
proliferate no matter whether they are stimulated with BM- or
PB-derived ZA-treated DC. Conversely, both BM- and PB-
derived ZA-treated DC induced the proliferation of PB Vg9Vd2
T cells.
Defective pAg reactivity is not a general feature of BM-resi-
dent Vg9Vd2 T cells. The distribution of Vg9Vd2 T-cell subsets
with low proliferative capacity (i.e., EM and TEMRA cells) was
similar in MM and CTRL BM, and BM Vg9Vd2 T cells from
CTRL and two patients with SEP, devoid of myeloma cells, effi-
ciently proliferate in response to ZA or BrHPP stimulation. The
latter is a synthetic pAg that does not require either monocytes or
DC to activate Vg9Vd2 T cells.12 Altogether, these data indicate
that defective pAg reactivity is mainly imputable to Vg9Vd2 T
Figure 4. pAg reactivity of BM Vg9Vd2 T cells in MM is not reinstated by inhibition or depletion of Tregs. (A) Total counts of viable Vg9Vd2 T cells per well
after 7-d stimulation of BMMC with IL-2 or ZA C IL2 in the presence or absence of soluble OX-40L (100 ng/mL). (B) Same as above in the presence or
absence of soluble anti-TGF-b (50 ng/mL). Both treatments failed to reinstate BM Vg9Vd2 T-cell pAg reactivity. (C) Total counts of viable Vg9Vd2 T cells
per well after 7-d stimulation of BMMC, BML, purified BMT cells, and BMT cells depleted of Tregs (BMTCD25¡) with BrHPP (3mM) C IL-2. BM Vg9Vd2 T-cell
proliferation was never reinstated even when purified BMT cells were depleted of Tregs.
www.tandfonline.com e1047580-5OncoImmunology
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cells and specifically restricted to MM patients with BM mye-
loma cell infiltration.
PD-1 expression was significantly increased in MM BM
Vg9Vd2 T cells. Increased PD-1 expression has been reported in
PB NK cells17 and T cells1820 of MM patients, but this is the first
report that show increased PD-1 expression in immune effector
cells at the tumor site. To date, PD-1 expression at the tumor site
has only been reported in the 5T33 murine model of myeloma in
which spleen and BM-derived CD4C and CD8C cells were
reported to be PD-1C, to have an exhausted phenotype,20 and to
include tumor-specific T cells.21 These results indicate that the
immune suppressive mechanisms operated by myeloma cells and
bystander cells in the tumor microenvironment are able to induce
PD-1 expression on both adaptive and innate immune effector cells.
Interestingly, PD-1 expression was predominant in CM
Vg9Vd2 T cells, which have the highest proliferative response to
pAg stimulation,22 and further increased after ZA stimulation.
These data indicate that MM BM Vg9Vd2 T cells are prone to
further upregulate the expression of immune checkpoint recep-
tors upon ineffective TCR engagement by pAgs.
Very little is known about the expression and function of PD-
1 in Vg9Vd2 T cells. Iwasaki et al.23 analyzed PD-1 expression
in PB Vg9Vd2 T cells after pAg stimulation in CTRL and one
breast-cancer patient. They found that PD-1C Vg9Vd2 T cells
produced less IFNg, showed lower cytotoxic activity and CD107
degranulation than PD-1¡ Vg9Vd2 T cells when challenged
with PD-L1C tumor target cells.23
We have shown that the MM BM microenvironment is abun-
dantly inhabited by PD-L1C cells. We have confirmed that the
majority of myeloma cells are PD-L1C16,18 but we have found
that a significant proportion of MDSC are also PD-L1C. This is
the first report showing PD-L1 expression in human MDSC at
Figure 5. The PD-1/PD-L1 suppressor pathway is operative in the BM of MM patients, and it is involved in the defective pAg reactivity of BM Vg9Vd2 T
cells. (A) PD-1 expression in PB and BM Vg9Vd2 T cells from CTRL and MM patients. MM BM Vg9Vd2 T cells showed a significantly higher PD1 expression
than Vg9Vd2 T cells from all the other sources. Statistically significant differences are marked with symbols (^P < 0.001; P D 0.001; *P < 0.001). (B) PD-1
expression in BM Vg9Vd2 T-cell subsets of MM patients identified according to CD27 and CD45RA expression (see also Table S1). CM Vg9Vd2 T cells
showed significantly higher PD-1 expression than all other subsets. Statistically significant differences are marked with symbols (*P < 0.001; P < 0.001;
^P D 0.001). (C) PD-1C expression in Vg9Vd2 T cells after 7-d stimulation of PBMC and BMMC from CTRL and MM patients with IL-2 or ZA C IL2. PD-1
expression significantly increased only in MM BM Vg9Vd2 T cells, which are anergic to pAg stimulation. Statistically significant differences are marked
with symbols (P D 0.005; *P D 0.006; x P D 0.02; ^P D 0.001). (D) Increased PD-L1 expression in myeloma cells and MDSC of MM patients. PD-L1 and PD-
1 expression were determined in BM CD138C cells of MM patients (left), and PB and BM MDSC from CTRL and MM patients (right). Statistically significant
differences are marked with symbols (P D 0.004; ^P D 0.03). (E) Representative dot-plots of PD-L1 expression in myeloma cells and MDSC from the BM
of MM patients. (F) Total counts of viable Vg9Vd2 T cells per well after 7-d stimulation of BMMC with IL-2 or ZA C IL2 in the presence of increasing con-
centrations of anti-PD1 mAb. A partial recovery of BM Vg9Vd2 T cell proliferation was observed after PD-1 blockade.
e1047580-6 Volume 4 Issue 11OncoImmunology
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the tumor site. Interestingly, PD-L1
expression in MM was significantly
higher in BM than PB MDSC, whereas
no difference was observed between PB
and BM in CTRL. This may explain why
Favaloro et al.24 who investigated only
PB samples did not find any significant
PD-L1 expression in MDSC of MM
patients.
The BM microenvironment is highly
hypoxic in MM,25 and it has recently been
shown that hypoxia induces PD-L1 upre-
gulation in splenic MDSC from tumor-
bearing mice, but not in MDSC from
peripheral lymphoid organs not infiltrated
by tumor cells.26 Interestingly, Myklebust
et al.27 have shown that histiocytes are
PD-L1C and deliver negative signals to
bystander T cells, which are PD-1C, in the
lymph nodes of follicular lymphoma
patients. Altogether, these data indicate
that immune responses at the tumor site
are blunted by direct interactions with
tumor cells, but also by the tumor-induced
recruitment of immune suppressive
bystander cells and vice versa, as shown by
the ability of BMSC to induce PD-L1
expression on myeloma cells.28
Previous reports have shown that PD-
1 blockade enhances in vitro T-cell
responses to autologous dendritic/mye-
loma fusion vaccines17 and to the NK
cell-mediated killing of autologous mye-
loma cells.18 In the 5T33 murine myeloma model, PD-L1 block-
ade in combination with myeloma cell vaccination and
autologous transplantation increased the survival of myeloma-
bearing mice,20 while PD-L1 blockade in combination with lym-
phopenia induced by non-myeloablative irradiation resulted in
the elimination of 5T33 myeloma cells both in the spleen and
the BM.21
We achieved an almost 2-fold proliferative response of BM
Vg9Vd2 T cells to ZA stimulation in the presence of anti-PD-1
mAb. The increased proliferation was matched by increased cell
surface CD107 mobilization implying an improved cytotoxic
activity of MM BM Vg9Vd2 T cells. By combining the increased
number of Vg9Vd2 T cells, the increased frequency of CD107C
Vg9Vd2 T cells, and the increased number of CD107 molecules
per cell, the cytotoxic potential of Vg9Vd2 T cells increased by
almost 5-fold after ZA stimulation in the presence of anti-PD-1
mAb. An increased effector to target ratio is highly desirable in
immunotherapy, and we have previously shown that Vg9Vd2 T
cell ability to kill myeloma cells is indeed limited by the propor-
tion of tumor target cells.6
The apparent discrepancy between the removal of PD-L1C
cells, such as myeloma cells or MDSC, and the unsuccessful
recovery of ZA-induced Vg9Vd2 T-cell proliferation can be
explained by the tonic signaling operated by PD-1 even in the
absence of engagement by PD-L1 and PD-L2. In tumor-infiltrat-
ing lymphocytes, which resemble MM BM Vg9Vd2 T cells,
PD-1 expression is maintained irrespective of PD-L1 or PD-L2
engagement provided that the TCR is continuously engaged,
whereas PD-1 expression fades away if TCR stimulation is inter-
rupted.29 Youngblood et al.30 have shown that PD-1 expression
is regulated by the methylation status of the PDCD1 region. In
chronic viral infections, the PDCD1 regulatory region remains
demethylated in functionally exhausted PD-1C CD8C cells. The
lack of remethylation is a consequence of sustained viral exposure
that exceeds the restricted timeframe for PDCD1 remethylation,
and PD-1 downregulation.30 Further evidence about negative
PD-1 tonic signaling was provided by Benson et al.17 who
showed in MM patients that a prolonged pre-incubation with
anti-PD-1 mAb and IL-2 is necessary to improve the cytotoxic
capacity of NK cells, whereas a short incubation period just
before mixing NK cells with myeloma cells to merely interrupt
PD-1/PD-L1 interactions is ineffective.
To build on the hypothesis that MM BM Vg9Vd2 T cells
have become PD-1C as a consequence of a prolonged TCR
engagement, we investigated IPP production in myeloma cells
and BMSC. Preliminary results indicate that MM BMSC
Figure 6. Anti-PD-1 treatment increases CD107 expression in BM Vg9Vd2 T cells of MM patients. (A)
CD107 expression (left panel) and mean fluorescence intensity (MFI) of CD107 expression (right
panel) in BM Vg9Vd2 T cells from CTRL and MM patients after 7-d stimulation with IL-2 or ZA C IL-2.
Both frequency and MFI values were significantly lower in MM than CTRL BM Vg9Vd2 T cells (*P <
0.05). (B) CD107 expression (left panel) and MFI values of CD107 expression (right panel) in MM BM
Vg9Vd2 T cells after stimulation with IL-2 or ZA C IL-2 in the absence or in the presence of 1 mg/mL
of anti-PD1 mAb. PD-1 inhibition significantly increased CD107 expression and MFI values in MM
BM Vg9Vd2 T cells (*P < 0.05).
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produce and release very high amounts of IPP, whereas CTRL
BMSC do not (Fig. S5). These data suggest that the BM micro-
environment is abundantly repleted with pAgs that can engage
Vg9Vd2 T cells. This engagement occurs within an immune sup-
pressive microenvironment under adverse conditions in terms of
costimulatory signals and/or cytokines leading to the functional
exhaustion of Vg9Vd2 T cells.
Vg9Vd2 T-cell dysfunction is an early event during evolution
of the disease, and does not fade away in clinical remission. This
finding was unexpected because the current opinion is that the
immune competence of MGUS individuals is preserved.31 NKT
cells, another subset of unconventional T cells sharing several
Vg9Vd2 T-cell characteristics, have been reported to be immune
competent in MGUS, but to become dysfunctional once the dis-
ease progresses to active MM.32
PD-1 expression was already present on BM Vg9Vd2 T cells
from MGUS and remained upregulated in MM-rem. Signifi-
cantly higher PD-1 expression was only observed in BM
Vg9Vd2 T cells from MM-rel. Rosenblatt et al.18 reported that
PD-1 expression on T cells returned to CTRL levels in MM
patients in complete remission after
autologous transplantation. This discrep-
ancy probably reflects the different cell
types investigated (T cells vs. Vg9Vd2 T
cells) and, especially, the different cell
sources of investigation (PB vs. BM).
MDSC frequency too was similar in
MGUS, compared with MM-dia and
MM-rel, whereas it was significantly
higher in MM-rem, compared with MM-
dia and MM-rel. No correlation was
found between myeloma cells and BM
MDSC frequencies in individual patients.
Ramachandran et al.11 too did not find
any correlation between myeloma cell
infiltration and the frequency of BM
MDSC. They showed in a mouse model
that MDSC starts to accumulate in BM as
early as one week after tumor inoculation
when the frequency of myeloma cells in
the BM is lower than 10% as in MGUS
individuals.11 Hence, the tumor burden
per se is not the major drive to induce BM
MDSC accumulation.
Interestingly, MDSC remain PD-L1C
also in MM-rem, indicating that the PD-
1/PD-L1 pathway is still operative and can
suppress Vg9Vd2 T-cell immune function
even when the majority of myeloma
cells have been cleared from BM. Our
results are consistent with those reported
by Zheng et al.33 who showed that the
homeostasis of systemic cytokines is already
unbalanced in MGUS individuals and
does not return to normality after
treatment.
BM Vg9Vd2 T-cell immune dysfunction already present in
MGUS may explain why the administration of ZA in high-risk
MGUS and smoldering myeloma decreased the frequency of bone
lesions, but not the transition rate to MM,34 and why the clinical tri-
als that have used ZA or other pAgs to intentionally activate
Vg9Vd2 T cells in vivo or ex vivo have fallen short of clinical expect-
ations even when patients were selected based on the in vitro reactiv-
ity of PB Vg9Vd2 T cells to pAg stimulation.35,36
Our results may help to develop more effective immune inter-
ventions in MM. The persistence of PD-1C Vg9Vd2 T cells indi-
cate that anti-PD-1 treatment can be beneficial to unleash the
effector functions not only of Vg9Vd2 T cells, but also of NK
cells and T cells. Anti-PD-1 treatment can be combined with
other strategies, such as pAg-induced Vg9Vd2 T-cell activation,
tumor vaccination17 and lymphodepletion.21
The persistence of PD-L1C MDSC can also hinder the effi-
cacy of immunotherapy during remission. Drugs, such as borte-
zomib or lenalidomide, are currently used for consolidation or
maintenance treatments but they have no effect on the frequency
and suppressor activity of MDSC.11 The finding that MDSC are
Figure 7. Anergy to pAg stimulation is an early and long-lasting dysfunction of BM Vg9Vd2 T cells. (A)
Total counts of viable Vg9Vd2 T cells per well after 7-d stimulation of BMMC with IL-2 or ZA C IL-2
from MGUS, MM in remission (MM-Rem), MM in relapse (MM-Rel), and two patients with solitary
extramedullary plasmocytoma (SEP). Values from MM at diagnosis (MM-Dia) already shown in
Figure 1 (panel A) are included for comparison. BM Vg9Vd2 T-cell anergy was already present in
MGUS and similar to that of MM-Dia, MM-Rem, and MM-Rel, whereas BM Vg9Vd2 T cells from SEP
samples responded to ZA C IL-2 stimulation. (B) PD-1 expression in BM Vg9Vd2 T cells was similar
in MGUS, MM-Dia, and MM-Rem, whereas MM-Rel showed significantly higher values than MM-Dia
(* P D 0.01). Values of MM-Dia from Figure 5 (panel A) are included for comparison. (C) MDSC fre-
quency in the BM of MGUS, MM-Dia, MM-Rem, and MM-Rel. Values of MM-Dia from Figure 2 (panel
A) are included for comparison. MM-Rem showed a significantly increased frequency of MDSC, com-
pared with MM-Dia and MM-Rel (*P < 0.001; P <0.001), whereas no differences were observed
between MGUS, MM-Dia, and MM-Rel. (D) PD-L1 expression in MDSC from the BM of MM-Dia, MM-
Rem, and MM-Rel. Values of MM-Dia from Figure 5D are included for comparison.
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PD-L1C raises the possibility of targeting these cells with anti-
PD-L1 mAb and eventually interrupting the negative signaling
performed by the PD-1/PD-L1 pathway.
Lastly, our findings provide the rationale to explore immune
checkpoint neutralization and Vg9Vd2 T-cell activation as non-
genotoxic approaches to boost anti-myeloma immune surveil-
lance in high-risk MGUS.
Materials and Methods
Patients
One-hundred and forty six MM patients and ten subjects with
MGUS entered the study. The MM series included 70 MM-dia,
52 MM-rem, and 24 MM-rel patients. BM and PB were investi-
gated head-to-head in 13 MM cases at diagnosis. The control
group (CTRL) included 28 PB samples from healthy blood
donors, kindly provided by the local Blood Bank and Transfu-
sion Service, 3 BM samples from individuals undergoing post-
degenerative or post-traumatic hip prosthesis implantation at the
local Traumatology and Orthopaedic Centre, and 15 frozen
human bone marrow mononuclear cell (BMMC) samples pur-
chased from Stem Cells Technologies (Vancouver, Canada).
The study was approved by the local Institutional Review
Board (DN 2012/388) and samples collected after the written
informed consent was obtained.
Immunophenotyping
Myeloma cells, Vg9Vd2 T cells and subsets (na€ıve, CM, EM,
and TEMRA), MDSC and subsets (PMN-MDSC and
M-MDSC), bone marrow stromal cells (BMSC), and Tregs were
immunophenotyped in BM and PB samples from MM and
CTRL as reported in the Table S1.
Vg9Vd2 T-cell activation and proliferation
PBMC and BMMC were incubated for 7 d with 10 IU/mL
IL-2 (Eurocetus, Milan, Italy) and 1 mM ZA (Novartis Pharma)
as previously reported.6 In selected experiments, 3 mM BrHPP
(kindly provided by Innate Pharma) was used to stimulate PB
and BM Vg9Vd2 T cells. Total counts of viable Vg9Vd2 T cells
and CD107 expression on Vg9Vd2 T cells were evaluated as pre-
viously reported.6,8 Vg9Vd2 T-cell proliferation and CD107
expression were also evaluated after stimulation of PBMC and
BMMC in the presence of anti-PD1 mAb or isotype control
(R&D Systems, Minneapolis, USA).
Vg9Vd2 T-cell stimulation by ZA-treated DC
ZA-treated DC were generated from CD14C cells isolated
from PB or BM samples and used to stimulate autologous PBL/
BML or PBT/BMT, as previously reported.9 Total counts of via-
ble Vg9Vd2 T cells were calculated on day 7 as reported above.
MDSC and Tregs inhibition and depletion
BMMC were cultured for 7 d with IL-2 and ZA in the absence
or presence of 50 mg/mL sildenafil, 1 mM 1-MT, 500 mM
L-NMMA, and 100 mM apocynin (all from Sigma Aldrich, Milan,
Italy) to inhibit phosphodiesterase-5 (PDE5), indoleamine-2,
3-dyoxigenase (IDO), inducible nitric oxide synthase (iNOS), and
reactive oxygen species (ROS), respectively. In depletion experi-
ments, MDSC were removed from BMMC by immunomagnetic
separation using a cocktail of CD33/CD11b/CD15-coated
microbeads (Miltenyi Biotech, Bologna, Italy).
To test the role of Tregs, BMMC were cultured for 7 d with
ZACIL-2 in the absence or presence of 100 ng/mL soluble recombi-
nant human OX40L (R&D Systems) or 50 ng/mL soluble recom-
binant human anti-TGF-b (Life Span Biosciences, Seattle, WA).
BrHPP and IL-2 were also used to stimulate BMMC,
CD14-depleted BMMC (BML), purified BM T cells (BMT),
and CD25-depleted BM T cells (BMTCD25¡) for 7 d.
Statistical analysis
The results are expressed as mean §SE. Differences between
groups were evaluated with the Wilcoxon–Mann–Whitney non-
parametric test for paired or unpaired samples, as appropriate,
and considered statistically significant for P values <0.05. Corre-
lation analyses were performed with the non-parametric Spear-
man Rank Order test with a cut-off P value <0.05. The
SigmaStat software (Systat Software Inc.. Richmond, USA) was
used for statistical analyses.
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